INSM vs. TMO: Insmed vs. Thermo Fisher Scientific Stock Comparison

November 11, 2026

How do Insmed (INSM) and Thermo Fisher Scientific (TMO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Insmed (INSM) and Thermo Fisher Scientific (TMO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INSM is classified in Biotechnology while TMO is classified in Life Sciences Tools & Services.

Company profile comparison for Insmed (INSM) and Thermo Fisher Scientific (TMO)
Profile Item	INSM	TMO
Name	Insmed Incorporated	Thermo Fisher Scientific Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	25.10 billion USD	257.42 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	June 1, 2000	March 17, 1980
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

INSM

TMO

GSPC

Insmed (INSM) vs. Thermo Fisher Scientific (TMO), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Insmed (INSM) and Thermo Fisher Scientific (TMO). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Insmed (INSM) and Thermo Fisher Scientific (TMO). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Insmed (INSM) and Thermo Fisher Scientific (TMO)
Metric	INSM	TMO
Total Return (1Y)	-39.17%	24.62%
Total Return (3Y, Annualized)	70.17%	17.34%
Total Return (5Y, Annualized)	28.96%	3.11%

Risk Profile

Drawdown History

INSM

TMO

GSPC

Insmed (INSM) vs. Thermo Fisher Scientific (TMO), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Insmed (INSM) and Thermo Fisher Scientific (TMO). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Insmed (INSM) and Thermo Fisher Scientific (TMO)
Metric	INSM	TMO
Volatility (1Y, Annualized)	63.09%	29.96%
Beta (5Y)	0.80	0.83
Max Drawdown (5Y)	-56.54%	-40.95%
Avg. Volume (3M)	2.76M	2.10M

Risk-Adjusted Performance

Risk-Return Positioning

INSM and TMO are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Insmed (INSM) and Thermo Fisher Scientific (TMO)
Metric	INSM	TMO
Sharpe Ratio (1Y)	-0.69	0.68
Sortino Ratio (1Y)	-1.04	1.02

Profitability

ROE (TTM)

Insmed (INSM) reports a negative ROE of -72.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Thermo Fisher Scientific (TMO) reports 13.38%, ranking against industry peers normally.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-72.45%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
INSM: -72.45%
Min: -167.77%

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.38%

Max: 109.18%
TMO: 13.38%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Insmed (INSM) vs. Thermo Fisher Scientific (TMO): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Insmed (INSM) reports a negative net margin of -39.85%, usually indicating a net loss over the period. Meanwhile Thermo Fisher Scientific (TMO) reports 14.94%, ranking against industry peers normally.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-39.85%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%
INSM: -39.85%

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.94%

Max: 18.05%
TMO: 14.94%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Insmed (INSM) vs. Thermo Fisher Scientific (TMO): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Insmed (INSM) reports a negative operating margin of -15.60%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Thermo Fisher Scientific (TMO) reports 20.19%, ranking against industry peers normally.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-15.60%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
INSM: -15.60%
Q1: -78.82%
Min: -207.40%

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.19%

Max: 83.12%
TMO: 20.19%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Insmed (INSM) vs. Thermo Fisher Scientific (TMO): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Insmed (INSM) and Thermo Fisher Scientific (TMO)
Metric	INSM	TMO
ROE (TTM)	-72.45%	13.38%
ROA (TTM)	-17.25%	5.19%
Net Margin (TTM)	-39.85%	14.94%
Operating Margin (TTM)	-15.60%	20.19%
Gross Margin (TTM)	84.40%	41.26%

Growth

Revenue Growth

Insmed (INSM) at 66.73% sits in the top revenue growth quartile, while Thermo Fisher Scientific (TMO) at 3.91% is closer to the peer norm — faster top-line expansion for INSM.

Insmed (INSM) vs. Thermo Fisher Scientific (TMO): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Thermo Fisher Scientific (TMO) reports EPS growth of 7.32%, ranked against its industry; Insmed (INSM) has no EPS growth figure this period.

Insmed (INSM) vs. Thermo Fisher Scientific (TMO): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Insmed (INSM) and Thermo Fisher Scientific (TMO)
Metric	INSM	TMO
Revenue Growth (YoY)	66.73%	3.91%
Revenue Growth (3Y CAGR)	35.20%	-0.27%
EPS Growth (YoY)	--	7.32%
EPS Growth (3Y CAGR)	--	0.21%

Financial Strength

Current Ratio (MRQ)

Insmed (INSM) at 2.86 keeps current ratio within its industry’s typical mid-range, while Thermo Fisher Scientific (TMO) at 1.81 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TMO.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.86

Max: 25.13
Q3: 12.13
Median: 5.52
INSM: 2.86
Q1: 2.47
Min: 0.10

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.81

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
TMO: 1.81
Min: 0.10

Insmed (INSM) vs. Thermo Fisher Scientific (TMO): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Insmed (INSM) at 1.01 and Thermo Fisher Scientific (TMO) at 0.75 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.01

Max: 1.42
INSM: 1.01
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.75

Max: 1.42
TMO: 0.75
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Insmed (INSM) vs. Thermo Fisher Scientific (TMO): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Insmed (INSM) and Thermo Fisher Scientific (TMO)
Metric	INSM	TMO
Current Ratio (MRQ)	2.86	1.81
Debt / Equity (MRQ)	1.01	0.75
Net Debt / EBITDA	--	2.91

Dividends

Dividend Yield (TTM)

Insmed (INSM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a yield of 0.27%, ranking against industry peers normally.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INSM: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.27%

TMO: 0.27%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Insmed (INSM) vs. Thermo Fisher Scientific (TMO): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Insmed (INSM) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a payout of 9.70%, ranking against industry peers normally.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INSM: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.70%

TMO: 9.70%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Insmed (INSM) vs. Thermo Fisher Scientific (TMO): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Insmed (INSM) and Thermo Fisher Scientific (TMO)
Metric	INSM	TMO
Dividend Yield (TTM)	0.00%	0.27%
Dividend Payout Ratio (TTM)	0.00%	9.70%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Thermo Fisher Scientific (TMO) trades at 36.64 times trailing earnings, ranked against its peers, while Insmed (INSM) has no P/E ratio this period.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
INSM: --

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.64

Max: 85.34
Q3: 43.46
TMO: 36.64
Median: 26.69
Q1: 13.30
Min: 0.07

Insmed (INSM) vs. Thermo Fisher Scientific (TMO): INSM does not report P/E ratio, so it has no value marker; TMO is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Insmed (INSM) at 16.52 and Thermo Fisher Scientific (TMO) at 5.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.52

Max: 58.18
Q3: 25.77
INSM: 16.52
Median: 7.30
Q1: 3.01
Min: 0.01

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.44

Max: 58.18
Q3: 25.77
Median: 7.30
TMO: 5.44
Q1: 3.01
Min: 0.01

Insmed (INSM) vs. Thermo Fisher Scientific (TMO): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Thermo Fisher Scientific (TMO) at 4.70 sits near its industry’s typical P/B ratio, while Insmed (INSM) at 34.55 prices above its benchmark range — INSM looks rich relative to book.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.55

INSM: 34.55
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

TMO

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70

Max: 13.53
Q3: 6.54
TMO: 4.70
Median: 3.25
Q1: 1.69
Min: -5.59

Insmed (INSM) vs. Thermo Fisher Scientific (TMO): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Insmed (INSM) and Thermo Fisher Scientific (TMO)
Metric	INSM	TMO
P/E Ratio (TTM)	--	36.64
P/S Ratio (TTM)	16.52	5.44
P/B Ratio (MRQ)	34.55	4.70
Free Cash Flow Yield (TTM)	-1.82%	2.50%